Report an error
Spotted something inaccurate in “TRAVERSE Trial Clarifies TRT Cardiac Safety While Flagging Secondary Risk Signals”? Tell us what’s wrong and we’ll check it against the original source.
This form is for factual corrections. We read every report but cannot reply individually.